Pubblicazioni

Expression of er, pgr, her-2, and ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy

2020 - CANCER CHEMOTHERAPY AND PHARMACOLOGY

Rossi, L.; Verrico, M.; Tomao, S.; Ricci, F.; Fontana, A.; Spinelli, G. P.; Colonna, M.; Vici, P.; Tomao, F.

All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma

2020 - CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cox, M. C.; Banchi, M.; Pelliccia, S.; Di Napoli, A.; Marcheselli, L.; Patti, C.; Anticoli Borza, P.; Battistini, R.; Di Gregorio, F.; Orlandi, P.; Bocci, G.

Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development

2019 - CANCER CHEMOTHERAPY AND PHARMACOLOGY

Angius, Gesuino; Tomao, Silverio; Stati, Valeria; Vici, Patrizia; Bianco, Vincenzo; Tomao, Federica

Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma

2016 - CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cereda, S; Milella, M; Cordio, S; Leone, F; Aprile, G; Galiano, A; Mosconi, S; Vasile, E; Santini, D; Belli, C; Auriemma, A; Novarino, A; Vaccaro, V; Martines, C; Marino, D; Lutrino, Se; Palazzo, V; Reinach, B; Aldrighetti, L; Reni, M

Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer. A single-institution experience

2015 - CANCER CHEMOTHERAPY AND PHARMACOLOGY

Petrioli, R; Francini, E; Roviello, F; Marrelli, D; Fiaschi, Ai; Laera, L; Rossi, G; Bianco, V; Brozzetti, Stefania; Roviello, G.

Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review

2015 - CANCER CHEMOTHERAPY AND PHARMACOLOGY

De Iuliis, Francesca; Salerno, Gerardo; Taglieri, Ludovica; Scarpa, Susanna